Methods: We applied two current electrodiagnostic criteria sets for demyelinating and axonal GBS subtypes in 55 patients who had at least two serial recordings in three motor and sensory nerves.
INTRODUCTION
Guillain-Barré syndrome (GBS) is divided in three major subtypes: acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN).
AIDP is most frequent in Western countries whereas AMAN is common in China and Japan. [1] [2] [3] [4] [5] 
AMAN and AMSAN have been associated with antecedent
Campylobacter jejuni (C. jejuni) infection and autoantibodies to gangliosides especially to GM1 and GD1a. [2] [3] [4] [5] [6] [7] In AMAN and AMSAN the pathology is consistent with an antibody-mediated primary axonal damage at the Ranvier node. [8] [9] [10] [11] AIDP, AMAN and AMSAN are difficult to distinguish on clinical grounds and electrophysiology plays a determinant role in GBS diagnosis, classification and in establishing the prognosis. AMAN is currently diagnosed by absence of demyelinating features and decrease of distal compound muscle action potential amplitude. [3, 4] However some GBS patients with IgG to gangliosides showed besides axonal features rapid resolution of conduction block (CB) and conduction slowing without development of temporal dispersion or restoration of F-waves without increased latency. [12] [13] [14] [15] These findings were thought to be incompatible with demyelination and remyelination and indicated that AMAN is characterized not only by axonal degeneration but also by "reversible conduction failure" possibly induced by anti-ganglioside antibodies at the axolemma of the Ranvier node. [12, 15] The aim of this study was to electrophysiologically classify an Italian GBS population according to the current criteria, to investigate how serial recordings changed the initial classification and to underline the possible pitfalls in electrodiagnosis of GBS subtypes.
METHODS

Patients
We reviewed the clinical and electrophysiological records of patients discharged with the diagnosis of GBS from the University Hospital of Chieti between January 1995 and June 2009 and selected patients with progressive weakness of more than one limb with or without sensory symptoms or signs, who had at least two electrophysiological recordings in at least three motor and three sensory nerves. Fifty-five patients fulfilled these requirements. All patients signed an informed consent for utilization of personal data, storage and assay of biological materials for research purposes.
Electrophysiology
Motor conduction studies were performed by a Nicolet Viking IV machine (Nicolet, USA). Amplitude and duration of negative peak of compound muscle action potential (CMAP) from distal (dCMAP) and proximal (pCMAP) stimulation, conduction velocity (CV), distal motor latency (DML) and minimal F-wave latency were measured. Sensory studies were performed antidromically in median and ulnar nerves, orthodromically in sural nerve. Amplitudes of sensory nerve action potentials (SNAPs) were measured baseline to negative peak. For DML, CV and F wave latency we defined the upper and lower limit of normal as the mean ±2.5 SD of control values of our laboratory. For CMAP and SNAP amplitude the lower limit of normal was calculated as the mean ±2.5 SD of the logarithmically transformed amplitudes of the controls. Electrophysiological findings in patients were expressed as percentages of upper and lower limits of controls. In serial recordings of the same patients dCMAP amplitude was considered significantly increased when higher than 50% of the value found at the first study. Electrophysiology was performed in each patient at least twice in the same motor and sensory nerves. The total number of tests was 170. The first test was performed within 15 days from onset of symptom (mean 9 days; range 2-15 days) and the results employed for the electrodiagnosis at first study. When a patient had more than one follow-up test the recording which we considered most informative was utilized for the final electrodiagnosis. The mean interval between disease onset and the most informative test was 28 days (range: 7-70 days). EMG of biceps brachialis, first dorsalis interosseous, quadriceps femoralis and tibialis anterior was performed in at least one follow up test and spontaneous activity was graded semi-quantitatively as absent, mild, moderate and abundant.
Electrodiagnostic criteria
In Table 1 are reported the electrodiagnostic criteria sets employed at initial test. In the Ho's criteria evidence of "unequivocal temporal dispersion" is enclosed among the parameters to assess demyelination. [3] As how much temporal dispersion of CMAP should be considered "unequivocal" was not defined we used an increased duration of negative peak of pCMAP ≥ 30% compared to dCMAP. [16] Hadden and colleagues replaced unequivocal temporal dispersion with CB defined as a pCMAP/dCMAP amplitude ratio less than 0.5. [4] AMSAN was diagnosed by absence of demyelinating features, as in the Ho's criteria, and reduction of sensory nerve action potential amplitude <50% of lower limit of normal in at least two nerves. [8, 17] Patient not fulfilling the criteria for AIDP, AMAN and AMSAN were classified as equivocal. The reasons for classification changes at follow-up are reported in the results section. 
Anti-ganglioside antibody testing
Serum IgG and IgM to gangliosides GM1, GD1a, GD1b, were tested in acute phase sera by ELISA. 
Statistical analysis
Patients were grouped according to final electrodiagnosis, presence or not of antecedent C. jejuni infection, and presence or not of anti-ganglioside antibodies.
Comparative analyses were made with Fisher's exact test. Results were considered significant if p < 0.05.
RESULTS
Electrodiagnosis at first test
At the first neurophysiologic test 37 of 55 patients (67%) fulfilled the Hadden's criteria for AIDP, 10 patients (9 AMAN, 1 AMSAN) (18%) for axonal GBS and 8 (14%) were equivocal. According to Ho's criteria 36 patients (65%) were classified as AIDP, 10 as axonal GBS (9 AMAN, 1 AMSAN) (18%) and 9 (16%) were equivocal ( Fig. 1) .
Follow-up and reasons for changes of electrodiagnosis
Thirty patients initially classified as AIDP according to both criteria did not change classification at follow-up. Two patients, initially classified according to both criteria as equivocal, developed definite demyelinating features and were reclassified as AIDP. Fourteen of 32 patients (23%) with final diagnosis of AIDP developed mild to moderate spontaneous activity in at least one muscle. The ten patients initially classified as axonal GBS showed at follow-up dCMAPs which substantially unchanged or further reduced, with some nerves becoming inexcitable, without the development of any demyelinating features and confirming a motor axonal degeneration pattern (Figs. 2A, 4A). All ten patients developed moderate to abundant spontaneous activity at EMG. Therefore none of these subjects changed the initial electrodiagnosis. Two patients according to Hadden's criteria and three patients according to Ho's criteria classified at the first study as equivocal developed amplitude reduction of dCMAPs and in one patient of SNAPs and were finally diagnosed as axonal subtypes. All three patients showed moderate to abundant spontaneous activity at EMG.
Three patients showed at the first study a progressive CMAP amplitude reduction along the nerve length ( Fig. 2B ) fulfilling in some segments the criterion for CB in at least one nerve. According to the Hadden's criteria, two patients were classified as AIDP whereas the other was classified as equivocal. According to Ho's criteria one patient was classified as AIDP and the other two were equivocal. Serial recordings showed that dCMAP amplitudes decreased becoming comparable to the pCMAPs with the disappearance of CB without development of excessive temporal dispersion or other features of demyelination (Fig. 2B ). All three patients showed abundant spontaneous activity at EMG. We interpreted this length-dependent CMAP amplitude reduction as due to progressive loss of excitability in fibres undergoing axonal degeneration and these patients were finally classified as axonal GBS. [19] [20] [21] Partial motor CB was found in intermediate nerve segments in at least two nerves in four patients and in one nerve in other two patients. CB was localized in six ulnar nerves of four patients in the segment across the elbow with slow CV (range 24-38 m/s) (Figs. 2D, 3 ). In five of these six patients DMLs were prolonged in 11 nerves (mean 122% of ULN, range 110-147%) reaching the cut-off for demyelination ( (Fig. 3) . In 17 nerves dCMAP amplitude promptly increased with a mean of 141% (range 67-350%) within a mean interval between the first study and follow-up of 9 days (range 6-17 days) (Figs. 2C, 4A ).
DMLs, when prolonged, returned to normal values within 3 weeks (Fig. 4B) . The time course of electrophysiological abnormalities in the nerves of these six patients was clearly different from what found in nerves of patients with AIDP and AMAN with axonal degeneration (Figs. 2, 4 ). Only two of six patients developed mild spontaneous activity at EMG. These six patients were finally classified as axonal GBS with reversible conduction failure. [12] [13] [14] [15] 
Final electrophysiological classification
Because of the of better definition of electrophysiologic abnormalities at follow-up, the recognition of the reversible physiologic conduction failure and of the lengthdependent CMAP reduction patterns as expressions of axonal pathology 13 subjects (24%) changed classification (Fig. 1) . Overall 32 patients (58%) were finally classified as AIDP, 21 (38%) as axonal GBS (18 AMAN, 3 AMSAN) and two (4%) remained equivocal (Fig. 1) . In the AIDP subtype 56% of patients had pain, 73% had paresthesias and 64% sensory loss. In AMAN subtype 38% of patients had pain, 16% had paresthesias and none sensory loss. All three AMSAN patients had paresthesias and sensory loss; pain was present in one patient.
Relations between final electrodiagnosis, antecedent C. jejuni infection and antiganglioside antibodies
Twenty-one of 51 (41%) GBS patients had antecedent C. jeuni infection. Sixteen of 19 patients (84%) with axonal GBS and 5 of 30 patients (17%) with AIDP had antecedent C. jeuni infection. The difference was highly significant (p=0.000004).
The two patients who remained equivocal at follow-up did not have antecedent C. jeuni infection.
Antibody to GM1 was present in eight AIDP and 12 axonal GBS (2 with reversible conduction failure). Antibody to GD1a was present in five AIDP and 13 axonal GBS (three with reversible conduction failure). Antibody to GD1b was present in six AIDP and eight axonal GBS (three with reversible conduction failure). Overall at least one antibody to gangliosides GM1, GD1a or GD1b was present in 28 of 55 (51%) GBS patients, in 19 of 21 (90%) axonal GBS and in 9 of 32 (28%) AIDP patients. The Indian patients applying the Ho'criteria to the results of a single test 86 % of patients had AIDP and 14% axonal GBS whereas in 41 patients from Israel, using the results of two studies performed within 4 weeks from onset, the percentage of AIDP was 63 % and of axonal GBS 37%. [22, 23] In the GBS series we report electrodiagnosis was almost identical at the first test with both criteria but at follow-up 24% patients changed classification. The main shifts being from AIDP and equivocal groups to the axonal group which resulted more than doubled. The principal reason was the individuation of CBs rapidly resolving without the development of dispersed CMAPs due to remyelinating, slow conducting, desynchronized components which are characteristic of the evolution of CB due to segmental demyelination. [24] [25] [26] This feature, denominated reversible conduction failure, has been described in some Japanese AMAN patients and in a GBS subtype named acute motor conduction block [30, 35, 36] An objection to the not demyelinating nature of reversible conduction failure might come from the observation that CV was slow at the site of CB in some nerves of patients we finally diagnosed as axonal GBS with reversible conduction failure. In these patients CV slowing was present from the first recording when CB was at maximum, CV rapidly increased with the decrease of CB and returned to normal range when CB had disappeared. Conduction slowing at CB sites may be a factitious phenomenon due to preferential block of large diameter fastest conducting fibres. The same explanation can be applied to the nerves showing prolonged DMLs which in sequential recordings quickly normalized in parallel with increased dCAMP amplitude. Alternatively sodium channel dysfunction, which is hypothesized to be at the basis of reversible conduction failure, may be responsible for conduction slowing.
In human poisoning by tetrodotoxin slow CVs, increased DMLs and reduced dCMAP amplitudes recover in few days without temporal dispersion possibly because of an uniform involvement of all fibers in the nerve resulting in synchronous slowing of impulse conduction. [37] Two patients were initially classified as AIDP because of progressive CMAP amplitude reduction along the nerve length fulfilling in some segments the criterion for CB. At follow up the dCMAP amplitude decreased and equalized the proximal CMAP without the development of temporal dispersion. This pattern was named by van der Meché and colleagues "length-dependent CMAP amplitude reduction" and initially thought to be due to demyelinating lesions scattered along the nerve followed by axonal degeneration.
[38] However this pattern is also consistent with an immunemediated primary axonal degeneration with progressive loss of excitability in fibres undergoing axonal degeneration. [19, 20, 21 , 39] The dCMAP is initially greater than the pCMAP because the injured axons are inexcitable above the lesion site whereas they remain excitable distally. The inexcitability progresses over few days distally till it reaches the nerve terminals. Other possible explanations are that CB may be due to an axonal dysfunction, as in reversible conduction failure, which progresses to axonal degeneration or imputable to an adjunctive distal axonal involvement. In any case the damage should be considered axonal in nature.
Because of the recognition of reversible conduction failure and length dependent CMAP amplitude reduction patterns a total of 7 patients shifted from the AIDP and equivocal groups to axonal GBS and none from axonal GBS to AIDP. In the study by
Hadden and colleagues six of ten patients initially classified in the axonal group were later reclassified as demyelinating, three equivocal and only one remained in the axonal group. Of the original demyelinating group 4% become axonal and 5% inexcitable. [4] This study was published in the same year of the paper on reversible conduction failure in axonal GBS and we think that, at least in part, the differences in results may be due to the lack of recognition of reversible conduction failure pattern. [4, 12] In the series we report antecedent C. jejuni infection and anti-ganglioside antibodies are more frequent in axonal GBS than in AIDP. Overall 79% of axonal GBS but only 13% of AIDP had antecedent C. jejuni infection and anti-gangliosides antibodies.
These results confirm that the three conditions: axonal GBS (including reversible conduction failure), antecedent C. jeuni infection and IgG to gangliosides GM1, GD1a, or GD1b are closely associated. [5] Hiraga and colleagues advanced the hypothesis that anti-ganglioside antibodies are associated to axonal degeneration or reversible conduction failure but not to true AIDP. [15] In our series all patients who shifted to the axonal group had anti-ganglioside antibodies. However 28% of patients finally classified as AIDP have anti-ganglioside antibodies. Reversible conduction failure is thought to be due to a transient attack of antibodies and complement limited at the excitable axolemma of Ranvier node but it is conceivable that an immunologic process, although specific, cannot have the "surgical" precision to completely spare the paranodal region. As a matter of fact detachment of terminal loops of paranodal myelin and lengthening of the nodal region has been shown in AMAN patients and in the experimental model. [10, 11, 31] This feature, although the primary pathology is on the axonal side, mimic paranodal demyelination and may explain the "grey zone" of patients with anti-ganglioside antibodies and some de-remyelinating features at electrophysiology fulfilling the criteria for AIDP.
This study demonstrates that in the early phase of GBS the distinction between AIDP and axonal GBS may be difficult or even impossible in some patients. Theoretically the Ho's criteria including excessive temporal dispersion but not CB should avoid the pitfalls due to reversible conduction failure and length-dependent CMAP amplitude reduction resulting more specific than Hadden's criteria for AIDP. However the fact that reversible conduction failure can also transiently slow CV and increase DML eliminates the advantage making the two criteria substantially equivalent.
In conclusion in GBS only serial electrophysiological studies allow the identification of pathophysiological mechanisms of muscle weakness and the correct classification in subtypes. More reliable electrophysiological criteria taking into consideration the reversible conduction failure pattern should be devised and validated in large populations. Ho et al.1985 [3] Patients must have one of the following in two or more nerves during the first 2 weeks of illness:
Motor conduction velocity<90%LLN (<85% if dCMAP<50%LLN) Distal motor latency >110 %ULN (>120% if dCMAP<100% LLN)
Evidence of unequivocal temporal dispersion F-response latency>120% b) Hadden et al.1998 [4] At least one of the following in each of at least two nerves, or at least two of the following in one nerve if all others inexcitable and dCMAP≥10% LLN: [3] No evidence of demyelination as defined in a dCMAP<80% LLN d) Hadden et al. 1998[4] None of the features of demyelination in any nerve as defined in b (except one demyelinating feature allowed in one nerve if dCMAP<10%LLN) dCMAP<80% LLN in at least 2 nerves AMSAN e) Feasby et al. 1993[8] , Rees et al. 1995 [17] No evidence of demyelination as defined in a dCMAP<80% LLN in at least 2 nerves SNAP <50% LLN in at least 2 nerves LLN: lower limit of normal; ULN: upper limit of normal; dCMAP: amplitude of compound muscle action potential after distal stimulation; pCMAP amplitude of compound muscle action potential after proximal stimulation; SNAP sensory nerve action potential. Vertical bars are standard errors. C) CMAPs recorded from the extensor digitorum brevis muscle after stimulation of peroneal nerve at ankle, below-fibular head and above-fibular head in a patient with antibodies to GD1b. On day six DML is prolonged and dCMAP amplitude reduced (1.6 mV). On day 12 DML is slightly prolonged and dCMAP amplitude is 106 % increased. On day 25 DML is in the normal range and dCMAP amplitude is 150 % increased compared to day six.
